QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism, Lawsuit Filed; April 13 Deadline Nears
MWN-AI** Summary
Hagens Berman, a national shareholder rights law firm, has intensified its investigation into uniQure N.V. (NASDAQ: QURE) following critical remarks by Food and Drug Administration (FDA) officials regarding the company's gene therapy candidate, AMT-130. The scrutiny comes concurrently with a securities class action lawsuit aimed at protecting investors who acquired shares between September 24, 2025, and October 31, 2025, during which they reportedly suffered losses. Investors are urged to act by the April 13, 2026, deadline to seek lead plaintiff status in the ongoing legal proceedings.
The investigation was prompted by an FDA official's statements during a recent media call, labeling AMT-130 as a "failed therapy" and accusing uniQure of distorting comparisons in clinical studies. Notably, the official rebuffed uniQure's claims regarding the ethical implications of sham surgeries, clarifying that the FDA's request did not involve invasive procedures like drilling holes in skulls. This contradicts previous assertions from the company regarding its interactions with the FDA.
The class action, titled Scocco v. uniQure N.V., alleges that uniQure misrepresented its regulatory standing and failed to disclose serious issues concerning the study designs and data utilization in its pivotal study for AMT-130. It specifically claims that uniQure misled investors about the approval process relating to external historical data as a control and purportedly concealed the necessity of a sham-controlled surgery arm.
As of now, uniQure faces significant scrutiny, and investors are advised to closely monitor developments in this case. Hagens Berman has dedicated resources for those seeking more information or wishing to submit their losses.
MWN-AI** Analysis
As the deadline of April 13, 2026, approaches, investors in uniQure N.V. (NASDAQ: QURE) should closely monitor the ongoing developments linked to the FDA's criticism and the recent class action lawsuit. The FDA’s rebuke of uniQure's lead gene therapy candidate, AMT-130, labels it a "failed therapy" due to alleged methodological flaws, which raises significant concerns about the company's future prospects.
Current allegations suggest that uniQure misrepresented its regulatory standing with the FDA, particularly regarding clinical trial requirements and timeline expectations for a Biologics License Application (BLA). These claims, if proven, could lead to further stock price erosion, following a dramatic 49% drop after the FDA's negative assessment was disclosed. The market's reaction may remain volatile as the class action progresses, making it critical for investors to act strategically.
Investors should consider the potential risks involved in holding QURE shares at this juncture. While partial recoveries may occur depending on future updates or legal outcomes, the lack of regulatory consensus and FDA support for AMT-130 suggests a precarious situation for the firm. As part of a prudent investment strategy, it may be wise to either re-evaluate positions in QURE or use stop-loss orders to mitigate potential losses.
Moreover, stakeholders should keep an eye on any communication from uniQure regarding their response to the FDA and how they plan to address litigation challenges. A transparent and constructive approach may benefit investor sentiment moving forward. In summary, while the long-term outlook for uniQure could improve with positive regulatory developments, the immediate landscape is fraught with uncertainty, making caution imperative for existing and prospective investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 (the "Class Period"). The firm reminds investors of the April 13, 2026, Lead Plaintiff deadline in the pending securities class action.
SUBMIT YOUR QURE LOSSES TO HBSS NOW
DEEP DIVE ANALYSIS: Visit Hagens Berman's dedicated QURE case page: www.hbsslaw.com/cases/uniqure, or view our latest video summary of the allegations: https://youtu.be/VWKl1BzabcE
The FDA Clash: "A Distorted or Manipulated Comparison"
On March 5 and 6, 2026, media outlets including The Wall Street Journal, CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.
The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the mind of FDA" instead of running a correct clinical study.
Key revelations from the March 6 disclosure include:
- Sham Surgery Mischaracterization: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, accusing the company of mischaracterizing the agency's request. The official clarified that the FDA did not ask to "drill holes in skulls," but rather required "one to three nicks in the scalp" under minimal anesthesia.
- Denial of Prior Agreement: While uniQure CEO Matt Kapusta described the sham surgery requirement as a "drastic change" from previous guidance, the FDA official pushed back, stating the agency "never agreed to accept this distorted comparison" using natural history as a comparator.
- Ineligibility for "Plausible Mechanism" Pathway: The official disputed AMT-130's eligibility for streamlined rare-disease pathways, noting it is not an individualized treatment.
The recent reports follow the filing of a securities class action suit.
Investors in uniQure (QURE) are encouraged to visit the Hagens Berman QURE Case Page to review the allegations in the pending litigation: www.hbsslaw.com/cases/uniqure
"The pending securities class action alleges a consistent pattern: that uniQure misrepresented its interactions with the FDA and used a pivotal study design that it knew the agency had not approved," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claim in the pending litigation.
Summary of QURE Class Action Allegations: The "Pivotal" Study Mirage
The securities class action, Scocco v. uniQure N.V., et al. (S.D.N.Y.), alleges that throughout the Class Period (Sept. 24, 2025 – Oct. 31, 2025), defendants failed to disclose:
- No Regulatory Consensus: That the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130.
- Hidden Requirements: That uniQure downplayed the necessity of a sham-controlled surgery arm for Phase III—a requirement the FDA now claims was never waived.
- Timeline Deception: That defendants misled investors regarding the timing of a Biologics License Application (BLA), which was rendered "unclear" once the lack of FDA agreement was revealed on November 3, 2025, sending the stock down 49%.
Critical Deadline: April 13, 2026
If you purchased uniQure ordinary shares during the Class Period (Sept. 24, 2025 – Oct. 31, 2025) and suffered losses, you have until April 13, 2026, to ask the Court to appoint you as Lead Plaintiff.
- Submit Your QURE Losses to HBSS Now
- Contact: Reed Kathrein at 844-916-0895 or email QURE@hbsslaw.com
If you'd like more information and answers to additional frequently asked questions about the uniQure case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding uniQure should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email QURE@hbslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
SOURCE Hagens Berman Sobol Shapiro LLP
FAQ**
What specific misrepresentations about regulatory agreements by uniQure N.V. (QURE) are highlighted in the securities class action lawsuit, and how might these impact investor confidence moving forward?
How does the FDA's characterization of uniQure N.V. (QURE) as a "failed therapy" affect the company's credibility and its potential to secure future approvals for AMT-130?
What are the implications of the FDA's requirement for a sham-controlled surgery arm for Phase III trials on uniQure N.V. (QURE) in terms of development timelines and regulatory strategy?
What steps can investors take to participate in the securities class action regarding uniQure N.V. (QURE), and what is the significance of the April 13, 2026 deadline?
**MWN-AI FAQ is based on asking OpenAI questions about uniQure N.V. (NASDAQ: QURE).
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
